MedTrace Logo

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

NCT00612209 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-07-23

No results posted yet for this study

Summary

This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.

Conditions

  • Cancer, Advanced Solid Tumors

Interventions

DRUG

ARQ 197

Treatment with ARQ 197

Sponsors & Collaborators

  • ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

    lead INDUSTRY

Principal Investigators

  • Johann DeBono, MBChB, FRCP · The Royal Marsden Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2010-01-31
Completion
2010-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612209 on ClinicalTrials.gov